Search results
Results from the WOW.Com Content Network
Reported side effects include injection site reactions, rash, and rarely toxic epidermal necrolysis. Gastrointestinal side effects generally include diarrhea and nausea and vomiting. Although C. difficile infection is a possible complication of aztreonam therapy, this antibiotic is associated with a low risk of developing C. difficile infection ...
Common side effects include nausea, diarrhea, constipation, headache, rash, and pain at the site of injection. [3] Serious side effects include Clostridioides difficile infection, seizures, and allergic reactions including anaphylaxis. [3] Those who are allergic to other β-lactam antibiotics are more likely to be allergic to meropenem as well. [3]
Severe side effects may include anaphylaxis, seizures, and Clostridioides difficile-associated diarrhea. [4] It is unclear if use during pregnancy is safe. [5] Meropenem works by blocking the construction of the bacterial cell wall while vaborbactam blocks the breakdown of meropenem by some beta-lactamases. [4]
However, many are associated with an infamous side effect: weight gain. Luckily, some antidepressants are less likely to cause weight gain than others. In fact, there are even some antidepressants ...
Adverse effects to monobactams can include skin rash and occasional abnormal liver functions. [citation needed]Monobactam antibiotics exhibit no IgE cross-reactivity reactions with penicillin but have shown some cross reactivity with cephalosporins, most notably ceftazidime, which contains an identical side chain as aztreonam. [9]
For all the buzz surrounding weight loss medications like semaglutide and tirzepatide, these drugs aren’t perfect. They come with a risk of side effects like nausea and diarrhea, along with ...
Typically, Ozempic side effects last for 8–12 weeks, during the time when you are gradually increasing your dose. Ozempic follows a dose titration schedule, where people start at a low 0.25 mg ...
The carbapenems imipenem and meropenem are recommended by the American Thoracic Society and the Infectious Disease Society of America as one of several first-line therapy options for people with late-onset hospital-acquired or ventilator-associated pneumonia, especially when Pseudomonas, Acinetobacter, or extended spectrum beta-lactamase ...